the use of statin drugs in patients with chronic kidney disease, combined with dyslipidemia
Clicks: 269
ID: 233924
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
269 views
60 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #20 of 39 articles by views in oncology letters
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
For medical treatment to reduce cholesterol levels by most international cardiology and nephrology associations recommended prescriptions of statin as monotherapy or combination with other drugs. The tоpic of this article is devoted to the comparative characteristic of this group of drugs for use in patients with chronic kidney disease associated with dyslipidemia. The main part of the article is an analysis of pharmacodynamics, efficacy, safety and expediency of using rosuvastatin, a drug from the group of the last generation of statins.
| Reference Key |
ivanov2015pokithe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;D.D. Ivanov;Ya.A. Dombrovskyi |
| Journal | oncology letters |
| Year | 2015 |
| DOI |
10.22141/2307-1257.0.2.12.2015.75374
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.